



T Cell and Tumor Immunotherapy

Guest Editors:

Dr. Raghendra Srivastava

Center for Immunotherapy and Precision Immuno-Oncology (CITI), Lerner Research Institute, Cleveland Clinic, 2111 E. 96th St. NB4-37, Cleveland, OH 44106, USA

Dr. Anil Shanker

Office for Research and Innovation, Meharry Medical College, Nashville, TN 37208, USA

Deadline for manuscript submissions:

31 July 2024

Message from the Guest Editors

Dear Colleagues,

There are billions of T cells in the body and they play a vital role in immunity. However, only a small percentage of T cells exert anti-tumor immune responses. The tumor microenvironment (TME) is an environment that is often infiltrated by T cells which attack tumor cells. However, these a small percentages of T cells encounter massive tumor-mediated immune suppression when they are infiltrated into the TME.

Overall, through genomic-based biomarkers, transcriptome analysis of TMEs, T cell receptor (TCR) diversity, and microbial diversity in TMEs, we are able to have a much better understanding of TMEs.

We believe that by furthering our knowledge on the TME, we can gain a better understanding of how cancer cells and immune cells interact with their environment, and how the immune system can be more effectively activated to fight cancer.

We would like to invite researchers to submit original research articles and reviews that will improve our understanding of TMEs. We recommend researchers submit work related to the TME, the diversity of TCRs, the diversity of microbes, and genomics-based correlation studies related to the TME.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)